Latest News
Amgen completes new Biomanufacturing facility in Singapore
21 November 2014 - United States-based Amgen has completed building its first Next-Generation Biomanufacturing facility, located in Singapore, it was reported on Thursday.

According to the company, this move represents a new stage of efficient and innovative production of medicines that treat serious diseases.

Biologic medicines are developed in living cells and the new Tuas facility has multiple technologies to allow greater speed, productivity and flexibility in commercial-scale manufacturing. The facility was constructed in less than two years and was completed in half the time required for conventional biomanufacturing plants. It utilises single-use bioreactors, disposable plastic containers, continuous purification processing and real-time quality analysis.

Login
Username:

Password: